

**IVIM reveals increased blood perfusion of liver metastases after oral intake of Salovum®**

e-Poster: 27

Congress: esmrmb2015 2015

Type: Scientific Paper

Topic: Preclinical Studies and Basic Science / Diffusion imaging

Authors: M. Montelius, O. Gustafsson, M. Andersson, E. Forssell-Aronsson, R. Hultborn, S. Ottosson, G. Carlsson, S. Lange, M. Ljungberg; Gothenburg/SE

MeSH:

Diffusion Magnetic Resonance Imaging [E01.370.350.500.150]

Neoplasm Metastasis [C04.697.650]

Gastrointestinal Stromal Tumors [C06.301.371.308]

Perfusion [E05.680]

Keywords: DW-MRI, Liver metastasis, Antisecretory factor AF, Treatment assessment

Any information contained in this pdf file is automatically generated from digital material submitted to e-Poster by third parties in the form of scientific presentations. References to any names, marks, products, or services of third parties or hypertext links to third-party sites or information are provided solely as a convenience to you and do not in any way constitute or imply ESMRMB's endorsement, sponsorship or recommendation of the third party, information, product, or service. ESMRMB is not responsible for the content of these pages and does not make any representations regarding the content or accuracy of material in this file.

As per copyright regulations, any unauthorised use of the material or parts thereof as well as commercial reproduction or multiple distribution by any traditional or electronically based reproduction/publication method is strictly prohibited.

You agree to defend, indemnify, and hold ESMRMB harmless from and against any and all claims, damages, costs, and expenses, including attorneys' fees, arising from or related to your use of these pages. Please note: Links to movies, ppt slideshows and any other multimedia files are not available in the pdf version of presentations.

www.esmrmb.org

1. Purpose

Elevated interstitial fluid pressure (IFP) in tumours impairs perfusion, which hinders anti-cancer drugs and oxygen to reach tumour cells¹⁻³. AF-16, a 16 amino acid long sequence from the amino terminal end of the endogenous protein Antisecretory Factor (AF), suppresses IFP in animal models of solid tumours⁴, and could improve drug delivery to tumour cells. Salovum[®], a spray-dried egg yolk powder with high content of antisecretory peptides, should be tested on humans, but requires non-invasive tumour IFP/perfusion assessment methods. The IntraVoxel Incoherent Motion (IVIM) model applied to multi-b DWI enables determination of tissue diffusion (D), pseudo-diffusion (D*) and voxel volume fraction of actively perfused capillaries (f)⁵.

The aim of this study was to investigate if f could be used to monitor changes induced by Salovum[®] in colorectal liver metastases in vivo.

2. Material and Methods

Previously untreated patients (n=6) with colorectal liver metastases were imaged before, and 24h after intake of 48g Salovum[®] dissolved in water, using IVIM-MRI (3T Philips, 16channel phased array receiver; Single-shot SE-EPI (breath-hold); FOV covering liver, 3x3x5mm³ voxels; TR/TE/NSA/SENSE=1900ms/50ms/2/2; 11 bvalues (0,10,20,30,40,50,75,100,200,300,400,500,600); acquisition time~10min.

MATLAB-based images processing comprised:

- 1) Inter-scan image registration (volume preserving free-form deformation⁶)
- 2) Voxelwise fitting of D and A [eq.2] to $S(b_{200-600})$ (for $b > 200$, [eq.1] reduces to [eq.2], assuming $D \ll D^*$), followed by fitting f and D* [eq.1] to $S(b_{0-600})$ keeping D and A fixed
- 3) Manual delineation of metastases (diameter > 2cm) on DWI (b=600), transfer of ROIs to corresponding f-maps for calculation of median ROI f before and after Salovum[®] intake
- 4) Mann-Whitney U-test for statistical significance (α -level=0.05)

3. Results

Liver and metastases were well visualised on DWIs and f-maps (Fig.1).

Median f in metastatic tissue increased after intake of Salovum[®] in 5/6 patients and decreased in one patient (Tab.1).

4. Conclusion

The results show that the proposed IVIM method is a promising, non-invasive tool for studying Salovum[®] induced changes in liver metastases in vivo. The increase in f was statistically significant but small, suggesting that additional time-points after Salovum[®] intake, dose escalation and intra-tumour effect heterogeneity should be investigated. The increased perfusion fraction in the liver metastases may offer an important "window of opportunity" for improved transport of drugs to tumour cells.

References

¹Rofstad, E.K., et al., *Neoplasia*, 2009

²Milosevic, M.F., et al., *Int J Radiat Oncol Biol Phys*, 1999

³Wiig, H., et al., *Scand J Clin Lab Invest*, 1982

⁴Al-Olama, M. et al., *Acta Oncol*, 2011

⁵Le Bihan, D., et al., *Radiology*, 1988

⁶Rueckert, D., et al., *IEEE Trans Med Imaging*, 1999

5. Mediafiles

Equations

$$S(b) = S_0 \left((1-f)e^{-bD} + fe^{-b(D+D^*)} \right) = Ae^{-bD} \left(1 + \frac{f}{1-f} e^{-bD^*} \right) \quad [eq. 1]$$

$$S(b) = Ae^{-bD}, \text{ where } A = S_0(1-f) \quad [eq. 2]$$

fig1.jpg




Figure 1. Left: Liver DWI (b=600) used to delineate all metastases (hyperintense regions) with a diameter > 2 cm. Right: Corresponding f -map where ROIs are superimposed and used to calculate median f of metastatic tissue.

tab1.jpg

Table 1. The median tumour perfusion fraction (f) increased in 5/6 patients (green), and decreased in 1 patient (red) after Salovum® intake. All changes were statistically significant with $p < 0.0001$

Median tumour f (%)		
	Before	After
Pat. 1	5.3	9.2
Pat. 2	3.7	4.4
Pat. 3	7.7	8.6
Pat. 4	5.5	6.2
Pat. 5	6.9	7.5
Pat. 6	9.2	5.6